Key result
Prazosin hydrochloride is an oral vasodilator for hypertension that causes less tachycardia than hydralazine but is limited by the risk of a first-dose syncopal reaction.
Prazosin is an oral vasodilator for hypertension that should be reserved for patients intolerant to hydralazine or sympathetic depressants due to the risk of first-dose syncope.
Reserve prazosin for hydralazine-intolerant patients due to syncope risk; leaves open its role versus modern agents in prospective trials.
Prazosin hydrochloride is an orally administered vasodilator that recently became available for the treatment of hypertension. It causes less tachycardia than hydralazine but may produce orthostatic hypotension, particularly after the initial dose. The role of prazosin in therapy is limited because of the risk of a first-dose syncopal reaction, and it appears to be indicated primarily in patients who cannot tolerate hydralazine hydrochloride or sympathetic depressant drugs. Like other antihypertensive agents, prazosin should be given with a diuretic. (JAMA238:157-159, 1977)
No takes yet. Share an insight, caveat, or question.
M. E. Kosman (1977) conducted a review in hypertension. Prazosin hydrochloride vs. hydralazine was evaluated. Prazosin hydrochloride is an oral vasodilator for hypertension that causes less tachycardia than hydralazine but is limited by the risk of a first-dose syncopal reaction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: